Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804

Nancy L. Bartlett, D. Niedzwiecki, J. L. Johnson, J. W. Friedberg, K. B. Johnson, K. van Besien, A. D. Zelenetz, B. D. Cheson, G. P. Canellos

Research output: Contribution to journalArticle

189 Scopus citations

Abstract

Background: Because of high single-agent activity and modest toxicity, we hypothesized the combination of gemcitabine (G), vinorelbine (V), and pegylated liposomal doxorubicin (D) would be an effective salvage therapy for Hodgkin's lymphoma (HL). Patients and methods: A total of 91 patients participated. GVD was administered on days 1 and 8 every 21 days at doses of G 1000 mg/m2, V 20 mg/m2, and D 15 mg/m2 for transplant-naive patients, and G 800 mg/m2, V 15 mg/m2, and D 10 mg/m2 for post-transplant patients. Results: The dose-limiting toxicity was mucositis for the transplant-naive patients and febrile neutropenia for post-transplant patients. The overall response rate (RR) for all patients was 70% [95% confidence interval (CI) 59.8, 79.7], with 19% complete remissions. The 4-year event-free and overall survival rates in transplant-naive patients treated with GVD followed by autologous transplant were 52% (95% CI 0.34, 0.68) and 70% (95% CI 0.49, 0.84), and in the patients in whom prior transplant failed, these were 10% (95% CI 0.03, 0.22) and 34% (95% CI 0.17, 0.52), respectively. Conclusions: GVD is a well-tolerated, active regimen for relapsed HL with results similar to those reported for more toxic regimens. High RRs in patients in whom prior transplant failed confirms this regimen's activity even in heavily pretreated patients.

Original languageEnglish
Pages (from-to)1071-1079
Number of pages9
JournalAnnals of Oncology
Volume18
Issue number6
DOIs
StatePublished - Jun 2007

Keywords

  • Gemcitabine
  • Hodgkin's lymphoma
  • Liposomal doxorubicin
  • Recurrent
  • Salvage therapy
  • Vinorelbine

Fingerprint Dive into the research topics of 'Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804'. Together they form a unique fingerprint.

  • Cite this

    Bartlett, N. L., Niedzwiecki, D., Johnson, J. L., Friedberg, J. W., Johnson, K. B., van Besien, K., Zelenetz, A. D., Cheson, B. D., & Canellos, G. P. (2007). Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Annals of Oncology, 18(6), 1071-1079. https://doi.org/10.1093/annonc/mdm090